logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Delcath Systems, Inc.

DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinicaā€¦ read more

Healthcare

Medical Devices

5 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$10.36

Price

-1.05%

-$0.11

$10.47

Previous Close

$10.51

Open

Premium

52w Discount
Market Cap

$362.406m

Small

Price/Earnings

115.1x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$68.600m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

$2.232m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

$0.04

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$104.986m

$116.876m

Assets

$11.890m

Liabilities

$993k

Debt
Debt to Assets

0.9%

0.1x

Debt to EBITDA
Free Cash Flow

$3.867m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.